AIM ImmunoTech Inc (AIM)
0.2326
-0.02
(-7.95%)
USD |
NYAM |
Nov 15, 12:53
AIM ImmunoTech Free Cash Flow (Quarterly): -3.237M for June 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -3.237M |
| March 31, 2024 | -4.865M |
| December 31, 2023 | -9.956M |
| September 30, 2023 | -5.855M |
| June 30, 2023 | -2.361M |
| March 31, 2023 | -3.68M |
| December 31, 2022 | -6.244M |
| September 30, 2022 | -4.988M |
| June 30, 2022 | -2.356M |
| March 31, 2022 | -2.791M |
| December 31, 2021 | -5.90M |
| September 30, 2021 | -3.544M |
| June 30, 2021 | -1.744M |
| March 31, 2021 | -3.41M |
| December 31, 2020 | -3.139M |
| September 30, 2020 | -2.993M |
| June 30, 2020 | -1.467M |
| March 31, 2020 | -3.364M |
| December 31, 2019 | -2.384M |
| September 30, 2019 | -2.567M |
| June 30, 2019 | -2.886M |
| March 31, 2019 | -1.595M |
| December 31, 2018 | -2.431M |
| September 30, 2018 | -3.034M |
| June 30, 2018 | -2.746M |
| Date | Value |
|---|---|
| March 31, 2018 | -2.556M |
| December 31, 2017 | -0.773M |
| September 30, 2017 | -1.919M |
| June 30, 2017 | -2.311M |
| March 31, 2017 | -3.007M |
| December 31, 2016 | -2.114M |
| September 30, 2016 | -3.061M |
| June 30, 2016 | -1.554M |
| March 31, 2016 | -1.105M |
| December 31, 2015 | -3.39M |
| September 30, 2015 | -3.507M |
| June 30, 2015 | -5.197M |
| March 31, 2015 | -4.449M |
| December 31, 2014 | -4.222M |
| September 30, 2014 | -3.912M |
| June 30, 2014 | -3.557M |
| March 31, 2014 | -3.035M |
| December 31, 2013 | -3.464M |
| September 30, 2013 | -4.292M |
| June 30, 2013 | -4.144M |
| March 31, 2013 | -6.141M |
| December 31, 2012 | -5.987M |
| September 30, 2012 | -4.401M |
| June 30, 2012 | -5.497M |
| March 31, 2012 | -3.217M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-9.956M
Minimum
Dec 2023
-1.467M
Maximum
Jun 2020
-3.909M
Average
-3.364M
Median
Mar 2020
Free Cash Flow (Quarterly) Benchmarks
| Perspective Therapeutics Inc | -9.917M |
| Protalix BioTherapeutics Inc | -3.782M |
| Electromed Inc | 4.443M |
| Xtant Medical Holdings Inc | -5.652M |
| Armata Pharmaceuticals Inc | -11.54M |